Recurrence Risk Estimator Valid for Acute Ischemic Stroke

This article originally appeared here.
Share this content:
Recurrence Risk Estimator Valid for Acute Ischemic Stroke
Recurrence Risk Estimator Valid for Acute Ischemic Stroke

THURSDAY, March 3, 2016 (HealthDay News) -- The Recurrence Risk Estimator (RRE) score is valid for identifying the risk of recurrence in patients with acute ischemic stroke, according to a study published online Feb. 29 in JAMA Neurology.

E. Murat Arsava, M.D., from the Hacettepe University Faculty of Medicine in Ankara, Turkey, and colleagues examined the validity of a prognostic score to predict early risk of stroke recurrence. The study was performed at three teaching hospitals in the United States, Brazil, and South Korea; 1,468 adult patients admitted within 72 hours of acute ischemic stroke were enrolled. The RRE score was calculated for each patient by an investigator who was blinded to recurrence status.

The researchers found that there were 59 recurrent stroke events within the cohort. The cumulative 90-day recurrence rate was 4.2 percent, with a mean RRE score of 2.2 in patients with recurrence and 1.0 in patients without recurrence. Increased risk of recurrence was observed with a higher RRE score (log-rank test, P < 0.001). For discrimination, the area under the receiver operating characteristic curve was 0.76. The RRE identified 48.4 percent of patients as high or low risk. The sensitivity and specificity were 38 and 93 percent, respectively, and 41 and 90 percent, respectively, for identifying low-risk and high-risk subsets.

"Our findings suggest that the RRE could be useful in identifying high- and low-risk patients for targeted stroke prevention," the authors write.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »